TriSalus Life Sciences Inc (TLSI)

Currency in USD
2.320
+0.145(+6.67%)
Closed·
2.3200.000(0.00%)
·
TLSI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.1902.370
52 wk Range
2.1657.950
Key Statistics
Prev. Close
2.32
Open
2.19
Day's Range
2.19-2.37
52 wk Range
2.165-7.95
Volume
539.26K
Average Volume (3m)
312.17K
1-Year Change
-54.2406%
Book Value / Share
0.011
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TLSI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.800
Upside
+236.21%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

TriSalus Life Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.800
(+236.21% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy10.00+331.03%12.00MaintainNov 11, 2026
Canaccord
Buy4.00+72.41%7.00MaintainNov 10, 2026
H.C. Wainwright
Buy12.00+417.24%11.00MaintainSep 23, 2026
H.C. Wainwright
Buy11.00+374.14%-New CoverageSep 09, 2026
Canaccord
Buy7.00+201.72%-MaintainJun 25, 2026

TriSalus Life Sciences Inc Earnings Call Summary for Q3/2026

  • TriSalus Q3 revenue rose 11% YoY to $12.9M but missed estimates by 9.85%; adjusted EPS of -$0.15 missed by 25%, sending shares down 26.55%
  • Company cut FY2026 revenue guidance to $46M-$48M, citing slower sales-force ramp in new territories and faster shift to super-selective Y90 procedures
  • Gross margin improved to 86% from 84%; adjusted EBITDA loss narrowed to $4.7M from $5.4M YoY, with R&D expenses down significantly to $3.2M
  • TriNav Advance received FDA clearance in September, now in limited market release; management expects 'meaningful double-digit growth' in 2027
  • Company maintains $41M cash position deemed sufficient for growth plan; CMS reimbursement changes in 2027 expected to improve Y90 procedure economics
Last Updated: 11/10/2026, 10:38 PM
Read Full Transcript

Earnings

Latest Release
Nov 10, 2026
EPS / Forecast
-0.15 / -0.12
Revenue / Forecast
12.9M / 14.31M
EPS Revisions
Last 90 days

TLSI Income Statement

Compare TLSI to Peers and Sector

Metrics to compare
TLSI
Peers
Sector
Relationship
P/E Ratio
−5.5x−1.2x−0.2x
PEG Ratio
−0.07−0.090.00
Price/Book
210.5x2.8x2.6x
Price / LTM Sales
3.1x8.0x2.6x
Upside (Analyst Target)
236.2%339.2%77.0%
Fair Value Upside
Unlock20.3%13.7%Unlock

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
6.37M10.32%14.77M
Other Institutional Investors
29.29M47.47%67.95M
Public Companies & Retail Investors
26.04M42.21%60.42M
Total
61.7M100.00%143.14M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
First Light Asset Management, LLC12.00%7,405,48617,181
Frankenius Equity AB11.33%6,989,74816,216

People Also Watch

2.120
NAUT
-2.30%
73.02
FORM
-10.83%
1.950
FRMI
-5.34%
2.335
ALEC
+1.52%
2.200
OVID
-5.98%

FAQ

What Is the TriSalus Life Sciences (TLSI) Stock Price Today?

The TriSalus Life Sciences stock price today is 2.320 USD.

What Stock Exchange Does TriSalus Life Sciences Trade On?

TriSalus Life Sciences is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for TriSalus Life Sciences?

The stock symbol for TriSalus Life Sciences is "TLSI."

What Is the TriSalus Life Sciences Market Cap?

As of today, TriSalus Life Sciences market cap is 143.140M USD.

What Is TriSalus Life Sciences's Earnings Per Share (TTM)?

The TriSalus Life Sciences EPS (TTM) is -0.49.

When Is the Next TriSalus Life Sciences Earnings Date?

TriSalus Life Sciences will release its next earnings report on Apr 05, 2027.

From a Technical Analysis Perspective, Is TLSI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has TriSalus Life Sciences Stock Split?

TriSalus Life Sciences has split 0 times.

How Many Employees Does TriSalus Life Sciences Have?

TriSalus Life Sciences has 102 employees.

What is the current trading status of TriSalus Life Sciences (TLSI)?

As of Nov 22, 2026, TriSalus Life Sciences (TLSI) is trading at a price of 2.320 USD, with a previous close of 2.320 USD. The stock has fluctuated within a day range of 2.190 USD to 2.370 USD, while its 52-week range spans from 2.165 USD to 7.950 USD.

What Is TriSalus Life Sciences (TLSI) Price Target According to Analysts?

The average 12-month price target for TriSalus Life Sciences is 7.800 USD, with a high estimate of 14 USD and a low estimate of 4 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +236.21% Upside potential.

What Is the TLSI Premarket Price?

TLSI's last pre-market stock price is 2.200 USD. The pre-market share volume is 13,810.000, and the stock has decreased by 0.025, or 1.150%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.